Asymchem Shares Surge Over 5% in Late Trading as Major TIDES CDMO Project Launches in Tianjin

Stock News15:48

Asymchem Laboratories (Tianjin) Co., Ltd. (06821) saw its shares rise more than 5% in late trading. At the time of writing, the stock had advanced 5.13% to HK$104.5, with a turnover of HK$118 million. The increase follows news that Asymchem's chemical macromolecule CDMO project has been established in the Tianjin Economic-Technological Development Area. This initiative is set to enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better addressing the diverse needs of global partners. Zheshang Securities previously noted that, given Asymchem's solid portfolio of small-molecule CDMO PPQ projects, the company's small-molecule CDMO business remains on a strong growth trajectory. Emerging segments, including peptide and oligonucleotide-related CDMO, ADC-related CDMO, and formulation CDMO, still possess substantial growth potential and earnings flexibility.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118017872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118017872","market":"sh","top_or_hot":-1,"title":"Asymchem Shares Surge Over 5% in Late Trading as Major TIDES CDMO Project Launches in Tianjin","media":"Stock News","content":"<p>Asymchem Laboratories (Tianjin) Co., Ltd. (06821) saw its shares rise more than 5% in late trading. At the time of writing, the stock had advanced 5.13% to HK$104.5, with a turnover of HK$118 million. The increase follows news that Asymchem's chemical macromolecule CDMO project has been established in the Tianjin Economic-Technological Development Area. This initiative is set to enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better addressing the diverse needs of global partners. Zheshang Securities previously noted that, given Asymchem's solid portfolio of small-molecule CDMO PPQ projects, the company's small-molecule CDMO business remains on a strong growth trajectory. Emerging segments, including peptide and oligonucleotide-related CDMO, ADC-related CDMO, and formulation CDMO, still possess substantial growth potential and earnings flexibility.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asymchem Shares Surge Over 5% in Late Trading as Major TIDES CDMO Project Launches in Tianjin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsymchem Shares Surge Over 5% in Late Trading as Major TIDES CDMO Project Launches in Tianjin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-27 15:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Asymchem Laboratories (Tianjin) Co., Ltd. (06821) saw its shares rise more than 5% in late trading. At the time of writing, the stock had advanced 5.13% to HK$104.5, with a turnover of HK$118 million. The increase follows news that Asymchem's chemical macromolecule CDMO project has been established in the Tianjin Economic-Technological Development Area. This initiative is set to enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better addressing the diverse needs of global partners. Zheshang Securities previously noted that, given Asymchem's solid portfolio of small-molecule CDMO PPQ projects, the company's small-molecule CDMO business remains on a strong growth trajectory. Emerging segments, including peptide and oligonucleotide-related CDMO, ADC-related CDMO, and formulation CDMO, still possess substantial growth potential and earnings flexibility.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1118017872","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118017872","pubTimestamp":1777276101,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Asymchem Laboratories (Tianjin) Co., Ltd. (06821) saw its shares rise more than 5% in late trading. At the time of writing, the stock had advanced 5.13% to HK$104.5, with a turnover of HK$118...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","CDMO":"Avid Bioservices, Inc.","06821":"凯莱英","BK4139":"生物科技","002821":"凯莱英","VXUS":"国际股票ETF-Vanguard","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0239":"医药制造","BK4588":"碎股","BK0132":"高送转概念","BK1191":"制药"},"translate_title":"Major TIDES CDMO项目在天津启动，凯莱英股价尾盘飙升逾5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMO":1,"002821":1,"06821":1,"VXUS":1},"content_text":"Asymchem Laboratories (Tianjin) Co., Ltd. (06821) saw its shares rise more than 5% in late trading. At the time of writing, the stock had advanced 5.13% to HK$104.5, with a turnover of HK$118 million. The increase follows news that Asymchem's chemical macromolecule CDMO project has been established in the Tianjin Economic-Technological Development Area. This initiative is set to enhance the company's integrated CDMO service capabilities for new molecular types such as peptides and oligonucleotides (TIDES), better addressing the diverse needs of global partners. Zheshang Securities previously noted that, given Asymchem's solid portfolio of small-molecule CDMO PPQ projects, the company's small-molecule CDMO business remains on a strong growth trajectory. Emerging segments, including peptide and oligonucleotide-related CDMO, ADC-related CDMO, and formulation CDMO, still possess substantial growth potential and earnings flexibility.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118017872","isCrawlerRequest":true}